Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Margaret Nelson

Nurse Practitioner, Acute Care Meridian, MS Nurse Practitioner

NPI 1326751678 CMS profile 11503022

2024 15Th St, Meridian, MS 39301

Open in the dashboard

General payments

$2,351

114 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Margaret Nelson of Meridian, MS is reported in the CMS Open Payments database as having received $2,351 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,234 58
2024 General $822 41
2023 General $295 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Margaret Nelson
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Margaret Nelson were reported at $1,234. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Margaret Nelson Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $0 $130 $44–$369 $149
2023 $295 $144 $49–$410 $160
2024 $822 $146 $48–$433 $164
2025 $1,234 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. GlaxoSmithKline, LLC. $504 28 payments
  2. AstraZeneca Pharmaceuticals LP $437 19 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $382 18 payments
  4. Genzyme Corporation $309 14 payments
  5. Mylan Specialty L.P. $180 8 payments
  6. Viatris Specialty LLC $163 9 payments
  7. Mallinckrodt Hospital Products Inc. $119 5 payments
  8. Amgen Inc. $99 5 payments
  9. Regeneron Healthcare Solutions, Inc. $76 4 payments
  10. Philips Electronics North America Corporation $39 2 payments
  11. Other $42 2 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,351 114 payments
Products named General payments · program years 2023–2025
  1. YUPELRI $343 17 payments
  2. TRELEGY ELLIPTA $322 24 payments
  3. DUPIXENT $309 14 payments
  4. FASENRA $283 11 payments
  5. OFEV Respiratory $246 12 payments
  6. AREXVY $192 13 payments
  7. NUCALA $182 4 payments
  8. AIRSUPRA $141 3 payments
  9. OFEV Respiratory $140 6 payments
  10. ACTHAR $119 5 payments
  11. Other $440 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$68,421

Medicare's payments for the services billed

Medicare patients

349

Average age 75

Services billed

1,216

188 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Heart failure 65%
Diabetes 55%
Chronic kidney disease 55%
Ischemic heart disease 54%
COPD 52%
Atrial fibrillation 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $225
$225 — —
YUPELRI
  • Mylan Specialty L.P. $157
$157 — —
DUPIXENT
  • GENZYME CORPORATION $104
  • Regeneron Healthcare Solutions, Inc. $17
$121 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $90
$90 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record